Emergence of Azole-Resistant Aspergillus fumigatus from Immunocompromised Hosts in India
Yubhisha Dabas1, Immaculata Xess2, Sameer Bakshi3
1Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India.
Abstract:
This prospective study shows that the rate of azole-resistant Aspergillus fumigatus (ARAF) in an immunocompromised Indian patient population with invasive aspergillosis (IA) is low, 6/706 (0.8%). This low rate supports the continued use of voriconazole as the first line of treatment. However, the ARAF isolates from India in this study exhibited three kinds of unreported cyp51A mutations, of which two were at hot spots, G54R and P216L, while one was at codon Y431C.
Insights
The rate of azole-resistant Aspergillus fumigatus in Indian patients with invasive aspergillosis is low. This finding supports voriconazole as a primary treatment, despite new cyp51A mutations observed in resistant strains.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Clinical Microbiology
Background:
- Invasive aspergillosis (IA) is a serious fungal infection, particularly in immunocompromised individuals.
- Azole antifungals are standard treatment, but resistance is a growing concern.
- Aspergillus fumigatus is the most common causative agent of IA.
Purpose of the Study:
- To determine the prevalence of azole-resistant Aspergillus fumigatus (ARAF) in Indian patients with IA.
- To identify novel mutations in the cyp51A gene associated with azole resistance.
- To inform antifungal treatment guidelines in the Indian subcontinent.
Main Methods:
- Prospective study design.
- Culturing and antifungal susceptibility testing of Aspergillus isolates from patients with IA.
- Molecular analysis of the cyp51A gene in resistant isolates.
Main Results:
- A low prevalence of ARAF was observed (0.8%, 6/706 patients).
- No previously reported cyp51A mutations were found in the susceptible isolates.
- Three novel cyp51A mutations were identified in the ARAF isolates: G54R, P216L, and Y431C.
Conclusions:
- The prevalence of ARAF in this Indian cohort is low, supporting voriconazole as a first-line agent.
- Novel cyp51A mutations in ARAF isolates highlight the need for ongoing surveillance.
- Further research is needed to understand the clinical impact of these new mutations.
Related Concept Videos
Emerging Adulthood
Introduction Cardiac Emergencies
Resistivity
Resistance
Applications of GIS: Disaster Management and Emergency Response
Equivalent Resistance


